Question special

As noted in my previous question, most of the mitochondrial proteins are encoded by nuclear DNA and not mtDNA. Certain types of mitochondrial disease arise not from primary defects with the mitochondria, but rather from mutations in the genome that are associated with mitochondrial function. This causes the same mitochondrial-deficient phenotype as mutations in mtDNA, but because mutations such as in PGC1 are not localized to the mitochondria, patients would not benefit from a mitochondrial donation. Will patients with mitochondrial diseases who would not benefit from the procedure be screened out? Is this technically feasible? Would the pathophysiology of each candidate's disease need to be worked out in order to only provide treatment to those who stand to benefit?